Related Experiment Video
Updated: Aug 8, 2026
09:29
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
Targeted therapy in colorectal cancer
Supriya Rajpal1, Alan P Venook
1University of California, San Francisco, Division of Hematology/Oncology, 505 Parnassus Avenue, Box 1270, San Francisco, CA 94143-1270, USA. srajpal@itsa.ucsf.edu
Clinical Advances in Hematology & Oncology : H&O
|May 27, 2006
Summary
Novel targeted therapies like bevacizumab and cetuximab improve metastatic colorectal cancer (CRC) treatment. While effective, their use requires careful consideration of toxicities and patient-specific factors for optimal outcomes.
Area of Science:
- Oncology
- Medical Research
Background:
- Metastatic colorectal cancer (CRC) treatment has advanced with chemotherapies, but limitations like toxicity and lack of specificity persist.
- Growth factor aberrations are implicated in CRC development, driving the creation of targeted therapies.
Purpose of the Study:
- To review the impact of novel targeted agents, bevacizumab and cetuximab, on metastatic colorectal cancer treatment.
- To discuss the efficacy, limitations, and future directions of these agents in CRC management.
Main Methods:
- Review of recent advancements in chemotherapeutic and targeted agents for metastatic CRC.
- Analysis of clinical trial data and FDA approvals for bevacizumab and cetuximab.
- Discussion of treatment strategies, including combination therapies and monotherapy.
Main Results:
- Bevacizumab enhances chemotherapy efficacy in metastatic CRC but carries risks like thromboembolic events and gastrointestinal perforations.
- Cetuximab combined with irinotecan is suitable for advanced CRC patients who have failed irinotecan; monotherapy is an option if irinotecan cannot be administered.
- Epidermal growth factor receptor (EGFR) status is currently mandated for cetuximab candidacy, though current assays may be suboptimal.
Conclusions:
- Bevacizumab and cetuximab represent significant progress in metastatic CRC treatment, offering new therapeutic options.
- Careful patient selection and ongoing research are crucial to optimize the use of these targeted agents and mitigate risks.
- Future research should focus on improved diagnostic techniques and exploring multi-targeted strategies for advanced CRC.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:15Drugs that Stabilize Microtubules
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...